We are investigating the Board of Directors of MYnd Analytics, Inc. (NasdaqCM: MYND) related to the sale of the company to Emmaus Life Sciences, Inc. Under the terms of the proposed transaction, MYND stockholders will own 5.9% of the combined company upon completion of the transaction.